AAAAAA

   
Results: 1-25 |
Results: 25
A PHASE-II TRIAL OF INTRATUMORAL INJECTION WITH AN E1B-DELETED ADENOVIRUS, ONYX-015, IN PATIENTS WITH RECURRENT, REFRACTORY HEAD AND NECK-CANCER
Authors: KAYE S NEMUNAITIS J GANLY I POSNER M VOKES E KUHN J HEISE C MAACK C KIRN D
Citation: S. Kaye et al., A PHASE-II TRIAL OF INTRATUMORAL INJECTION WITH AN E1B-DELETED ADENOVIRUS, ONYX-015, IN PATIENTS WITH RECURRENT, REFRACTORY HEAD AND NECK-CANCER, Annals of oncology, 9, 1998, pp. 61-61
A PHASE-II TRIAL OF INTRATUMORAL INJECTION WITH AN E1B-DELETED ADENOVIRUS, ONYX-015, IN PATIENTS WITH RECURRENT, REFRACTORY HEAD AND NECK-CANCER
Authors: KAYE S NEMUNAITIS J GANLY I POSNER M VOKES E KUHN J HEISE C MAACK C KIRN D
Citation: S. Kaye et al., A PHASE-II TRIAL OF INTRATUMORAL INJECTION WITH AN E1B-DELETED ADENOVIRUS, ONYX-015, IN PATIENTS WITH RECURRENT, REFRACTORY HEAD AND NECK-CANCER, Annals of oncology, 9, 1998, pp. 326-326
A PHASE-II STUDY OF 72 HOUR CONTINUOUS-INFUSION (CI) FLAVOPIRIDOL (FP) IN METASTATIC RENAL-CELL CARCINOMA (RCC)
Authors: STADLER WM LIEBOWITZ DN VOGELZANG NJ AMATO R SOSMAN J TABER D VOKES E
Citation: Wm. Stadler et al., A PHASE-II STUDY OF 72 HOUR CONTINUOUS-INFUSION (CI) FLAVOPIRIDOL (FP) IN METASTATIC RENAL-CELL CARCINOMA (RCC), Annals of oncology, 9, 1998, pp. 429-429
PHASE-II TRIAL OF PROLONGED INFUSION GEMCITABINE (GEMZAR) IN ADVANCEDCOLORECTAL-CARCINOMA - IN-VIVO PROOF OF A PHARMACOLOGICAL PRINCIPLE
Authors: MANI S KNOST J GIBBONS J GARCIA J SCIORTINO D TABER D SCHILSKY R TEMBE S VOL M VOKES E
Citation: S. Mani et al., PHASE-II TRIAL OF PROLONGED INFUSION GEMCITABINE (GEMZAR) IN ADVANCEDCOLORECTAL-CARCINOMA - IN-VIVO PROOF OF A PHARMACOLOGICAL PRINCIPLE, Annals of oncology, 9, 1998, pp. 598-598
A PHASE-II TRIAL OF UFT WITH LEUCOVORIN FOR THE TREATMENT OF ADVANCEDPANCREATIC, HEPATOCELLULAR AND BILIARY CANCER - A UNIVERSITY-OF-CHICAGO PHASE-II CONSORTIUM STUDY
Authors: MANI S KUGLER J SCIORTINO D GARCIA J ANSARI R TEMBE S MICHELASSI F POSNER M SHULMAN K SCHILSKY R VOKES E BENNER S
Citation: S. Mani et al., A PHASE-II TRIAL OF UFT WITH LEUCOVORIN FOR THE TREATMENT OF ADVANCEDPANCREATIC, HEPATOCELLULAR AND BILIARY CANCER - A UNIVERSITY-OF-CHICAGO PHASE-II CONSORTIUM STUDY, Annals of oncology, 9, 1998, pp. 624-624
PHASE-II STUDY OF DOXORUBICIN (DOX) AND PACLITAXEL (TAX) GIVEN PRIOR TO STANDARD CISPLATIN (P) AND ETOPOSIDE (E) IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER (SCLC)
Authors: MAUER A LAD T HOFFMAN P ARIETA R GABRYS J SCIORTINO D VOKES E
Citation: A. Mauer et al., PHASE-II STUDY OF DOXORUBICIN (DOX) AND PACLITAXEL (TAX) GIVEN PRIOR TO STANDARD CISPLATIN (P) AND ETOPOSIDE (E) IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER (SCLC), Annals of oncology, 9, 1998, pp. 655-655
PHASE-II TRIAL OF PYRAZOLOACRIDINE (NSC-3661400) IN PATIENTS WITH ADVANCED PANCREATIC AND HEPATOBILIARY CANCER
Authors: MANI S MICHELASSI F WADE J KUGLER J GERSTNER J GEOFFROY F ANSARI R ARRIETA R MURGO A SCHILSKY R VOKES E
Citation: S. Mani et al., PHASE-II TRIAL OF PYRAZOLOACRIDINE (NSC-3661400) IN PATIENTS WITH ADVANCED PANCREATIC AND HEPATOBILIARY CANCER, Annals of oncology, 9, 1998, pp. 673-673
RECOMMENDED GUIDELINES FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED DIARRHEA
Authors: WADLER S BENSON AB ENGELKING C CATALANO R FIELD M KORNBLAU SM MITCHELL E RUBIN J TROTTA P VOKES E
Citation: S. Wadler et al., RECOMMENDED GUIDELINES FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED DIARRHEA, Journal of clinical oncology, 16(9), 1998, pp. 3169-3178
PHASE-III TRIAL OF MODULATION OF CISPLATIN FLUOROURACIL CHEMOTHERAPY BY INTERFERON-ALPHA-2B IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK-CANCER/
Authors: SCHRIJVERS D JOHNSON J JIMINEZ U GORE M KOSMIDIS P SZPIRGLAS H ROBBINS K OLIVEIRA J LEWENSOHN R SCHULLER J RIVIERE A ARVAY C LANGECKER P JACOB H CVITKOVIC E VOKES E
Citation: D. Schrijvers et al., PHASE-III TRIAL OF MODULATION OF CISPLATIN FLUOROURACIL CHEMOTHERAPY BY INTERFERON-ALPHA-2B IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK-CANCER/, Journal of clinical oncology, 16(3), 1998, pp. 1054-1059
A PHASE-II TRIAL OF VINORELBINE IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
Authors: SAXMAN S MANN B CANFIELD V LOEHRER P VOKES E
Citation: S. Saxman et al., A PHASE-II TRIAL OF VINORELBINE IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK, American journal of clinical oncology, 21(4), 1998, pp. 398-400
PERFORMANCE AND QUALITY-OF-LIFE OUTCOME IN PATIENTS COMPLETING CONCOMITANT CHEMORADIOTHERAPY PROTOCOLS FOR HEAD AND NECK-CANCER
Authors: LIST MA MUMBY P HARAF D SISTON A MICK R MACCRACKEN E VOKES E
Citation: Ma. List et al., PERFORMANCE AND QUALITY-OF-LIFE OUTCOME IN PATIENTS COMPLETING CONCOMITANT CHEMORADIOTHERAPY PROTOCOLS FOR HEAD AND NECK-CANCER, Quality of life research, 6(3), 1997, pp. 274-284
SEXUAL FUNCTIONING AND HEAD AND NECK-CANCER
Authors: SISTON AK LIST MA SCHLESER R VOKES E
Citation: Ak. Siston et al., SEXUAL FUNCTIONING AND HEAD AND NECK-CANCER, Journal of psychosocial oncology, 15(3-4), 1997, pp. 107-122
LONG-TERM RESPONSE TO CRISNATOL MESYLATE IN PATIENTS WITH GLIOMA
Authors: NEW P VOKES E ROGERS L BAZAN C HOHNEKER J EBLE M VILK P
Citation: P. New et al., LONG-TERM RESPONSE TO CRISNATOL MESYLATE IN PATIENTS WITH GLIOMA, Investigational new drugs, 15(4), 1997, pp. 343-352
INTENSIVE MULTIMODALITY THERAPY CARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA
Authors: MAUER A HARAF D FERGUSON M HOFFMAN P OLAK J DRINKARD L MASTERS G VOKES E
Citation: A. Mauer et al., INTENSIVE MULTIMODALITY THERAPY CARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA, Journal of investigative medicine, 44(7), 1996, pp. 396-396
THE PERFORMANCE STATUS SCALE FOR HEAD AND NECK-CANCER PATIENTS AND THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY HEAD AND NECK SCALE - A STUDY OF UTILITY AND VALIDITY
Authors: LIST MA DANTONIO LL CELLA DF SISTON A MUMBY P HARAF D VOKES E
Citation: Ma. List et al., THE PERFORMANCE STATUS SCALE FOR HEAD AND NECK-CANCER PATIENTS AND THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY HEAD AND NECK SCALE - A STUDY OF UTILITY AND VALIDITY, Cancer, 77(11), 1996, pp. 2294-2301
SURGICAL-MANAGEMENT OF THE HEAD AND NECK-CANCER PATIENT FOLLOWING CONCOMITANT MULTIMODALITY THERAPY
Authors: PANJE WR NAMON AJ VOKES E HARAF DJ WEICHSELBAUM RR
Citation: Wr. Panje et al., SURGICAL-MANAGEMENT OF THE HEAD AND NECK-CANCER PATIENT FOLLOWING CONCOMITANT MULTIMODALITY THERAPY, The Laryngoscope, 105(1), 1995, pp. 97-101
SWALLOWING FUNCTION FOLLOWING MULTISPECIALTY ORGAN PRESERVATION TREATMENT OF ADVANCED HEAD AND NECK-CANCER
Authors: KARNELL MP MACCRACKEN E MORAN WJ VOKES E HARAF D PANJE WR
Citation: Mp. Karnell et al., SWALLOWING FUNCTION FOLLOWING MULTISPECIALTY ORGAN PRESERVATION TREATMENT OF ADVANCED HEAD AND NECK-CANCER, Oncology Reports, 1(3), 1994, pp. 597-601
RANDOMIZED COMPARISON OF NEOADJUVANT CISPLATIN AND FLUOROURACIL INFUSION FOLLOWED BY RADIATION VERSUS CONCOMITANT TREATMENT IN ADVANCED HEAD AND NECK-CANCER
Authors: TAYLOR SG MURTHY AK VANNETZEL JM COLIN P DRAY M CALDARELLI DD SHOTT S VOKES E SHOWEL JL HUTCHINSON JC WITT TR GRIEM KL HARTSELL WF KIES MS MITTAL B REBISCHUNG JL COUPEZ DJ DESPHIEUX JL BOBIN S LEPAJOLEC C
Citation: Sg. Taylor et al., RANDOMIZED COMPARISON OF NEOADJUVANT CISPLATIN AND FLUOROURACIL INFUSION FOLLOWED BY RADIATION VERSUS CONCOMITANT TREATMENT IN ADVANCED HEAD AND NECK-CANCER, Journal of clinical oncology, 12(2), 1994, pp. 385-395
CONCOMITANT AND ALTERNATING RADIATION-THERAPY (RT) AND CHEMOTHERAPY (CT) FOR INOPERABLE, MO, NONSMALL CELL LUNG CANCERS (NSCLC) - A CONSENSUS REPORT
Authors: MIRIMANOFF RO RUBIN P COX JD GANDARA D GRUNENWALD D HAZUKA M JASSEM J KOMAKI R MATTSON K MCDONALD S MORNEX F PALAZZI M PAVY JJ REBOUL F SHAW E STORME G STOUT R SUTEDJA T TROVO MD VOKES E ZANELLI G
Citation: Ro. Mirimanoff et al., CONCOMITANT AND ALTERNATING RADIATION-THERAPY (RT) AND CHEMOTHERAPY (CT) FOR INOPERABLE, MO, NONSMALL CELL LUNG CANCERS (NSCLC) - A CONSENSUS REPORT, Lung cancer, 11, 1994, pp. 5-8
A PHASE-I STUDY OF CHEMORADIOTHERAPY WITH CISPLATIN (CDDP) AND NAVELBINE (NVB) FOR ADVANCED MALIGNANCIES OF THE CHEST
Authors: MASTERS G DRINKARD L HOFFMAN P GOLOMB H HARAF D LAW N OLAK J FERGUSON M WATSON S VOKES E
Citation: G. Masters et al., A PHASE-I STUDY OF CHEMORADIOTHERAPY WITH CISPLATIN (CDDP) AND NAVELBINE (NVB) FOR ADVANCED MALIGNANCIES OF THE CHEST, Clinical research, 42(3), 1994, pp. 10000378-10000378
PHASE-I DOSE-ESCALATION STUDY OF TUMOR-NECROSIS-FACTOR AND RADIATION
Authors: HALLAHAN DE WEICHSELBAUM RR RUBIN SJ VIJAYKUMAR S SAMUELS B PHILLIPS R KUFE D OBRIEN S VOKES E
Citation: De. Hallahan et al., PHASE-I DOSE-ESCALATION STUDY OF TUMOR-NECROSIS-FACTOR AND RADIATION, International journal of radiation oncology, biology, physics, 27, 1993, pp. 184-184
TIME-DOSE ANALYSIS OF LOCAL-CONTROL FOR ADVANCED HEAD AND NECK NEOPLASMS TREATED WITH CONCOMITANT CHEMORADIOTHERAPY ON AN ALTERNATE WEEK SCHEDULE
Authors: WONG W HARAF D VOKES E MICK R WEICHSELBAUM R
Citation: W. Wong et al., TIME-DOSE ANALYSIS OF LOCAL-CONTROL FOR ADVANCED HEAD AND NECK NEOPLASMS TREATED WITH CONCOMITANT CHEMORADIOTHERAPY ON AN ALTERNATE WEEK SCHEDULE, International journal of radiation oncology, biology, physics, 27, 1993, pp. 241-242
LONG-TERM EXPERIENCE WITH CISPLATIN-BASED INDUCTION CHEMOTHERAPY AND CONCOMITANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK-CANCER(HNC)
Authors: STUPP R HARAF D KOZLOFF M MCEVILLY J WEICHSELBAUM R VOKES E
Citation: R. Stupp et al., LONG-TERM EXPERIENCE WITH CISPLATIN-BASED INDUCTION CHEMOTHERAPY AND CONCOMITANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK-CANCER(HNC), Clinical research, 41(3), 1993, pp. 10000647-10000647
A PHASE-I-II TRIAL OF CISPLATIN (CDDP), 5-FLUOROURACIL (5FU), LEUCOVORIN, (PFL), AND NAVELBINE (NVB) IN ADVANCED NON-SMALL-CELL LUNG-CANCER(NSCLC)
Authors: DRINKARD L SAMUELS B HOFFMAN P GOLOMB H BITRAN J FERGUSON M WATSON S HARAF D VOKES E
Citation: L. Drinkard et al., A PHASE-I-II TRIAL OF CISPLATIN (CDDP), 5-FLUOROURACIL (5FU), LEUCOVORIN, (PFL), AND NAVELBINE (NVB) IN ADVANCED NON-SMALL-CELL LUNG-CANCER(NSCLC), Clinical research, 41(3), 1993, pp. 10000704-10000704
P53 MUTATION DOES NOT CORRELATE WITH RADIOSENSITIVITY IN 24 HEAD AND NECK-CANCER CELL-LINES
Authors: BRACHMAN DG BECKETT M GRAVES D HARAF D VOKES E WEICHSELBAUM RR
Citation: Dg. Brachman et al., P53 MUTATION DOES NOT CORRELATE WITH RADIOSENSITIVITY IN 24 HEAD AND NECK-CANCER CELL-LINES, Cancer research, 53(16), 1993, pp. 3667-3669
Risultati: 1-25 |